Kandy Therapeutics
Breakthrough treatment for chronic debilitating Women’s Health conditions
KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of NT-814 as a breakthrough medicine for the treatment of chronic debilitating Women’s Health conditions.
NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS).
NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd, a separate legal entity. The new company will advance the development of NT-814 into Phase 2b in the lead indication PMS while also exploring its potential in other Women’s Health indications. All formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 have been transferred to the new company.
CEO Mary Kerr
Advent Contact Kaasim Mahmood
Exited Investment
U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant
Press Release. U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant The New Drug Application (NDA) for elinzanetant, an investigational compound for the treatment of moderate…
Read More
Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies
Press Release. Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies OASIS 1 and 2 pivotal studies evaluating investigational…
Read More
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
Press Release. Phase 2b dose range finding study showed rapid and highly significant reductions in the frequency of hot flashes (primary endpoint) for the full 12-week treatment period~ Reduction…
Read More
